Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. od Santini, V, Prebet, T, Fenaux, P, Gattermann, N, Nilsson, L, Pfeilstöcker, M, Vyas, P, List, A

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia od Dickinson, M, Cherif, H, Fenaux, P, Mittelman, M, Verma, A, Portella, M, Burgess, P, Ramos, P, Choi, J, Platzbecker, U, Support Study Investigators

Erratum to Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo [Cancer Cell, 25 (2014) 794-808] od Woll, P, Kjällquist, U, Chowdhury, O, Doolittle, H, Wedge, D, Thongjuea, S, Erlandsson, R, Ngara, M, Anderson, K, Deng, Q, Mead, A, Stenson, L, Giustacchini, A, Duarte, S, Giannoulatou, E, Taylor, S, Karimi, M, Scharenberg, C, Mortera-Blanco, T, Macaulay, I, Clark, S, Dybedal, I, Josefsen, D, Fenaux, P, Hokland, P

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo od Woll, P, Kjällquist, U, Chowdhury, O, Doolittle, H, Wedge, D, Thongjuea, S, Erlandsson, R, Ngara, M, Anderson, K, Deng, Q, Mead, A, Stenson, L, Giustacchini, A, Duarte, S, Giannoulatou, E, Taylor, S, Karimi, M, Scharenberg, C, Mortera-Blanco, T, Macaulay, I, Clark, S, Dybedal, I, Josefsen, D, Fenaux, P, Hokland, P

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the Internatio... od Efficace, F, Buckstein, R, Abel, GA, Giesinger, JM, Fenaux, P, Bewersdorf, JP, Brunner, AM, Bejar, R, Borate, U, DeZern, AE, Greenberg, P, Roboz, GJ, Savona, MR, Sparano, F, Boultwood, J, Komrokji, R, Sallman, DA, Xie, Z, Sanz, G, Carraway, HE, Taylor, J, Nimer, SD, Della Porta, MG, Santini, V

Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis od McGraw, KL, Cheng, C-H, Chen, YA, Hou, H-A, Nilsson, B, Genovese, G, Cluzeau, T, Pellagatti, A, Przychodzen, BP, Mallo, M, Arenillas, L, Mohamedali, A, Adès, L, Sallman, DA, Padron, E, Sokol, L, Moreilhon, C, Raynaud, S, Tien, H-F, Boultwood, J, Ebert, BL, Sole, F, Fenaux, P, Mufti, GJ, Maciejewski, JP

BCL-2 inhibitor ABT-737 effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a NRAS/BCL-2 mouse model of hig... od Gorombei, P, Guidez, F, Ganesan, S, Chiquet, M, Pellagatti, A, Goursaud, L, Tekin, N, Beurlet, S, Patel, S, Guerenne, L, Le Pogam, C, Setterblad, N, de la Grange, P, LeBoeuf, C, Janin, A, Noguera, M-E, Sarda-Mantel, L, Merlet, P, Boultwood, J, Konopleva, M, Andreeff, M, West, R, Pla, M, Adès, L, Fenaux, P, Krief, P, Chomienne, C, Omidvar, N, Padua, RA

Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice od Leroy, B, Ballinger, M, Baran-Marszak, F, Bond, G, Braithwaite, A, Concin, N, Donehower, L, El-Deiry, W, Fenaux, P, Gaidano, G, Langerød, A, Hellstrom-Lindberg, E, Iggo, R, Lehmann-Che, J, Mai, P, Malkin, D, Moll, U, Myers, J, Nichols, K, Pospisilova, S, Ashton-Prolla, P, Rossi, D, Savage, S, Strong, L, Tonin, P, Zeillinger, R, Zenz, T, Fraumeni, J, Taschner, P, Hainaut, P, Soussi, T

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes od Garcia-Manero, G, Santini, V, Almeida, A, Platzbecker, U, Jonasova, A, Silverman, LR, Falantes, J, Reda, G, Buccisano, F, Fenaux, P, Buckstein, R, Diez Campelo, M, Larsen, S, Valcarcel, D, Vyas, P, Giai, V, Olíva, EN, Shortt, J, Niederwieser, D, Mittelman, M, Fianchi, L, La Torre, I, Zhong, J, Laille, E, Lopes de Menezes, D, Skikne, B, Beach, CL, Giagounidis, A

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS od Malcovati, L, Stevenson, K, Papaemmanuil, E, Neuberg, D, Bejar, R, Boultwood, J, Bowen, DT, Campbell, PJ, Ebert, BL, Fenaux, P, Haferlach, T, Heuser, M, Jansen, JH, Komrokji, RS, Maciejewski, JP, Walter, MJ, Fontenay, M, Garcia-Manero, G, Graubert, TA, Karsan, A, Meggendorfer, M, Pellagatti, A, Sallman, DA, Savona, MR, Sekeres, M, Steensma, DP, Tauro, S, Thol, F, Vyas, P, Van de Loosdrecht, AA, Haase, DT, Tuechler, H, Greenberg, PL, Ogawa, S, Hellstrom-Lindberg, ES, Cazzola, M

Luspatercept in patients with lower-risk myelodysplastic syndromes od Fenaux, P, Platzbecker, U, Mufti, GJ, Garcia-Manero, G, Buckstein, R, Santini, V, Díez-Campelo, M, Finelli, C, Cazzola, M, Ilhan, O, Sekeres, MA, Falantes, JF, Arrizabalaga, B, Salvi, F, Giai, V, Vyas, P, Bowen, D, Selleslag, D, DeZern, AE, Jurcic, JG, Germing, U, Götze, KS, Quesnel, B, Beyne-Rauzy, O, Cluzeau, T, Voso, M-T, Mazure, D, Vellenga, E, Greenberg, PL, Hellström-Lindberg, E, Zeidan, AM, Adès, L, Verma, A, Savona, MR, Laadem, A, Benzohra, A, Zhang, J, Rampersad, A, Dunshee, DR, Linde, PG, Sherman, ML, Komrokji, RS, List, AF

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. od Woll, P, Kjällquist, U, Chowdhury, O, Doolittle, H, Wedge, D, Thongjuea, S, Erlandsson, R, Ngara, M, Anderson, K, Deng, Q, Mead, A, Stenson, L, Giustacchini, A, Duarte, S, Giannoulatou, E, Taylor, S, Karimi, M, Scharenberg, C, Mortera-Blanco, T, Macaulay, I, Clark, SA, Dybedal, I, Josefsen, D, Fenaux, P, Hokland, P, Holm, MS, Cazzola, M, Malcovati, L, Tauro, S, Bowen, D, Boultwood, J, Pellagatti, A, Pimanda, J, Unnikrishnan, A, Vyas, P, Göhring, G, Schlegelberger, B, Tobiasson, M, Kvalheim, G, Constantinescu, SN, Nerlov, C, Nilsson, L, Campbell, P, Sandberg, R, Papaemmanuil, E, Hellström-Lindberg, E, Linnarsson, S, Jacobsen, S

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MD... od Stahl, M, Bewersdorf, JP, Xie, Z, Porta, MGD, Komrokji, R, Xu, ML, Abdel-Wahab, O, Taylor, J, Steensma, DP, Starczynowski, DT, Sekeres, MA, Sanz, G, Sallman, DA, Roboz, GJ, Platzbecker, U, Patnaik, MM, Padron, E, Odenike, O, Nimer, SD, Nazha, A, Majeti, R, Loghavi, S, Little, RF, List, AF, Kim, TK, Hourigan, CS, Hasserjian, RP, Halene, S, Griffiths, EA, Gore, SD, Greenberg, P, Figueroa, ME, Fenaux, P, Efficace, F, DeZern, AE, Daver, NG, Churpek, JE, Carraway, HE, Buckstein, R, Brunner, AM, Boultwood, J, Borate, U, Bejar, R, Bennett, JM, Wei, AH, Santini, V, Savona, MR, Zeidan, AM

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts od Zeidan, AM, Boddu, PC, Patnaik, MM, Bewersdorf, JP, Stahl, M, Rampal, RK, Shallis, R, Steensma, DP, Savona, MR, Sekeres, MA, Roboz, GJ, DeAngelo, DJ, Schuh, AC, Padron, E, Zeidner, JF, Walter, RB, Onida, F, Fathi, A, DeZern, A, Hobbs, G, Stein, EM, Vyas, P, Wei, AH, Bowen, DT, Montesinos, P, Griffiths, EA, Verma, AK, Keyzner, A, Bar-Natan, M, Navada, SC, Kremyanskaya, M, Goldberg, AD, Al-Kali, A, Heaney, ML, Nazha, A, Salman, H, Luger, S, Pratz, KW, Konig, H, Komrokji, R, Deininger, M, Cirici, BX, Bhatt, VR, Silverman, LR, Erba, HP, Fenaux, P, Platzbecker, U, Santini, V, Wang, ES, Tallman, MS

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome od Hoeks, M, Bagguley, T, van Marrewijk, C, Smith, A, Bowen, D, Culligan, D, Kolade, S, Symeonidis, A, Garelius, H, Spanoudakis, M, Langemeijer, S, Roelofs, R, Wiegerinck, E, Tatic, A, Killick, S, Panagiotidis, P, Stanca, O, Hellström-Lindberg, E, Cermak, J, van der Klauw, M, Wouters, H, van Kraaij, M, Blijlevens, N, Swinkels, DW, de Witte, T, EUMDS Registry Participants, Stauder, R, Walder, A, Pfeilstöcker, M, Schoenmetzler-Makrai, A, Burgstaller, S, Thaler, J, Mandac Rogulj, I, Krejci, M, Voglova, J, Rohon, P, Jonasova, A, Cermak, J, Mikulenkova, D, Hochova, I, Jensen, PD, Holm, MS, Kjeldsen, L, Dufva, IH, Vestergaard, H, Re, D, Slama, B, Fenaux, P, Choufi, B, Cheze, S, Vyas, P

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups od Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, International Working Group For Mds Molecular Prognostic Committee